Bob handles corporate transactions and provides regulatory counseling relating to health care services, pharmaceuticals and medical devices. He also assists in health care-related litigation, investigations and disputes, and in legislative and regulatory policy issues and related advocacy and drafting.
A core element of Bob’s practice is negotiation of agreements relating to pricing and/or provision of prescription drugs and other health care services. These include:
- Rebate agreements between pharmaceutical manufacturers and pharmacy benefit managers (PBMs), managed care organizations (MCOs) or other payers, including agreements relating to formulary rebates, market share rebates, outcomes-based rebates (a/k/a value-based rebates), rebates on drugs covered under a medical benefit (including rebates on Part B drugs covered under Medicare Advantage plans), and Medicaid supplemental rebates;
Qualifications
Récompenses et distinctions
- Named a "Life Sciences Star" (Regulatory) in the LMG Life Science Guide (2016-2021) and a “Life Sciences Star” for Healthcare Pricing & Reimbursement in the LMG Life Sciences Guide (2022-2023)
- Recognized by Nightingales Healthcare News as one of America's "Outstanding Healthcare Transaction Lawyers" in 2008
Notable Quotes
- 11 May 2018 "Trump Vows Cheaper Drugs 'Very Soon,' But That's Unlikely" Law360